Last reviewed · How we verify

Levobupivacaine 0,5%

ASST Gaetano Pini-CTO · FDA-approved active Small molecule

Levobupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.

Levobupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local and regional anesthesia for surgical procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic nameLevobupivacaine 0,5%
SponsorASST Gaetano Pini-CTO
Drug classLocal anesthetic (amide)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

As the S-enantiomer of bupivacaine, levobupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve fibers. This prevents depolarization and transmission of nerve impulses, resulting in local anesthesia. Levobupivacaine has a lower cardiotoxicity profile compared to racemic bupivacaine due to reduced myocardial sodium channel blockade.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: